BR112014008727A2 - composto, composição farmacêutica, uso do composto ou sal, métodos para o tratamento de e/ou a prevenção de uma doença ou condição, para a intensificação da resposta imune em um indivíduo, e para regular por regulação positiva uma resposta imune a jak/stat em um indivíduo - Google Patents

composto, composição farmacêutica, uso do composto ou sal, métodos para o tratamento de e/ou a prevenção de uma doença ou condição, para a intensificação da resposta imune em um indivíduo, e para regular por regulação positiva uma resposta imune a jak/stat em um indivíduo

Info

Publication number
BR112014008727A2
BR112014008727A2 BR112014008727A BR112014008727A BR112014008727A2 BR 112014008727 A2 BR112014008727 A2 BR 112014008727A2 BR 112014008727 A BR112014008727 A BR 112014008727A BR 112014008727 A BR112014008727 A BR 112014008727A BR 112014008727 A2 BR112014008727 A2 BR 112014008727A2
Authority
BR
Brazil
Prior art keywords
individual
immune response
compound
methods
jak
Prior art date
Application number
BR112014008727A
Other languages
English (en)
Inventor
Lindsey Banka Anna
Brooks Moore Christopher
Gregory Burroughs Eric
D Dickson Hamilton
Hofland Hans
Botyanszki Janos
Therrien Jean-Philippe
Daniel Keicher Jesse
Bradford Shotwell John
George Catalano John
J Gartland Margaret
David Tallant Matthew
Hamatake Robert
You Shihyun
Huang Chern Wendy
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of BR112014008727A2 publication Critical patent/BR112014008727A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Abstract

1 / 1 resumo “composto, composiã‡ãƒo farmacãšutica, uso do composto ou sal, mã‰todos para o tratamento de e/ou a prevenã‡ãƒo de uma doenã‡a ou condiã‡ãƒo, para a intensificaã‡ãƒo da resposta imune em um indivãduo, e para regular por regulaã‡ãƒo positiva uma resposta imune a jak/stat em um indivãduo” sã£o fornecidos certos compostos e seus sais farmaceuticamente aceitã¡veis, suas composiã§ãµes farmacãªuticas, seus mã©todos de preparaã§ã£o, e seu uso para o tratamento de infecã§ãµes virais.
BR112014008727A 2011-10-21 2012-10-19 composto, composição farmacêutica, uso do composto ou sal, métodos para o tratamento de e/ou a prevenção de uma doença ou condição, para a intensificação da resposta imune em um indivíduo, e para regular por regulação positiva uma resposta imune a jak/stat em um indivíduo BR112014008727A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161549784P 2011-10-21 2011-10-21
US201261692431P 2012-08-23 2012-08-23
PCT/US2012/060971 WO2013059559A2 (en) 2011-10-21 2012-10-19 Compounds and methods for enhancing innate immune responses

Publications (1)

Publication Number Publication Date
BR112014008727A2 true BR112014008727A2 (pt) 2017-04-25

Family

ID=48141628

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014008727A BR112014008727A2 (pt) 2011-10-21 2012-10-19 composto, composição farmacêutica, uso do composto ou sal, métodos para o tratamento de e/ou a prevenção de uma doença ou condição, para a intensificação da resposta imune em um indivíduo, e para regular por regulação positiva uma resposta imune a jak/stat em um indivíduo

Country Status (22)

Country Link
US (1) US20140249143A1 (pt)
EP (1) EP2768506A4 (pt)
JP (1) JP2014532626A (pt)
KR (1) KR20140094559A (pt)
CN (1) CN103957910A (pt)
AR (1) AR088793A1 (pt)
AU (1) AU2012325971B2 (pt)
BR (1) BR112014008727A2 (pt)
CA (1) CA2851801A1 (pt)
CL (1) CL2014001016A1 (pt)
CO (1) CO6910198A2 (pt)
CR (1) CR20140175A (pt)
DO (1) DOP2014000081A (pt)
EA (1) EA201490610A1 (pt)
IL (1) IL231894A0 (pt)
MX (1) MX2014004814A (pt)
PE (1) PE20141359A1 (pt)
SG (2) SG10201505664WA (pt)
TW (2) TW201333003A (pt)
UY (1) UY34406A (pt)
WO (1) WO2013059559A2 (pt)
ZA (1) ZA201402392B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103333168B (zh) * 2013-07-23 2015-08-05 清华大学 一种酰胺类化合物及其制备方法与应用
US9758518B2 (en) 2015-03-04 2017-09-12 Pimera, Inc. Compositions, uses and methods for making them
WO2016053893A1 (en) * 2014-09-29 2016-04-07 The Trustees Of The University Of Pennsylvania Antivirals against molluscum contagiosum virus
CN104529893B (zh) * 2014-12-30 2016-08-24 中国科学技术大学 一类可以作为高尔基体细胞器探针的喹啉染料
CN105175277B (zh) * 2015-05-18 2018-04-03 中山大学肿瘤防治中心 一种3‑磷酸甘油醛脱氢酶的抑制剂及其制备方法和应用
WO2018043747A1 (ja) * 2016-09-05 2018-03-08 国立大学法人京都大学 抗ｂ型肝炎ウイルス剤
JP2020512975A (ja) 2017-03-28 2020-04-30 ピメラ，インク． Ｐｏｌ１阻害剤の新規な結晶形態
UA127747C2 (uk) 2018-10-23 2023-12-20 Басф Се Трициклічні пестицидні сполуки
CN114732823B (zh) * 2019-03-13 2023-05-23 中国人民解放军军事科学院军事医学研究院 氨基葡萄糖及其衍生物作为抗病毒药物的应用
US20230141433A1 (en) 2020-04-14 2023-05-11 Basf Se Tricyclic pesticidal compounds
WO2022049521A1 (en) * 2020-09-03 2022-03-10 Glaxosmithkline Intellectual Property Development Limited Imidazonaphthyridines and imidazopyridopyrimidines as ifnar2 agonists for treating sars-cov-2 infections
WO2022175425A1 (en) 2021-02-22 2022-08-25 Glaxosmithkline Intellectual Property Development Limited Inhaled mtor kinase inhibitors for use in the treatment or the prevention of a respiratory rna virus infection
AU2022367432A1 (en) 2021-10-14 2024-05-02 Incyte Corporation Quinoline compounds as inhibitors of kras
WO2023244672A1 (en) 2022-06-14 2023-12-21 Assembly Biosciences, Inc. 2-(imidazo[1, 2-a]1,8-naphthyridin-8-yl)-1,3,4-oxadiazole derivatives as enhancers of innate immune response for the treatment of viral infections

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL59104A (en) * 1979-02-09 1984-02-29 Roussel Uclaf Heterotricyclic derivatives,process for their preparation and pharmaceutical compositions incorporating them
US4492697A (en) * 1983-08-16 1985-01-08 Ayerst, Mckenna & Harrison, Inc. 4H-Imidazo[2,3-c]pyrido[2,3-e][1,4]oxazine derivatives
US6110929A (en) * 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
EP1492790A1 (en) * 2002-04-03 2005-01-05 F. Hoffmann-La Roche Ag Imidazo fused compounds
US8592368B2 (en) * 2003-12-19 2013-11-26 University Of South Florida JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection
DE102005019181A1 (de) * 2005-04-25 2006-10-26 Novartis Ag Peptid-Deformylase (PDF) Inhibitoren 1
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
JP5481671B2 (ja) * 2009-03-31 2014-04-23 ダイキン工業株式会社 高分子アクチュエータ素子用電極膜及びそれを有する高分子アクチュエータ素子
GB0919432D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
GB201002409D0 (en) * 2010-02-12 2010-03-31 Univ Nottingham Methods

Also Published As

Publication number Publication date
WO2013059559A3 (en) 2013-11-14
JP2014532626A (ja) 2014-12-08
AU2012325971B2 (en) 2016-03-31
US20140249143A1 (en) 2014-09-04
CR20140175A (es) 2014-06-03
CL2014001016A1 (es) 2015-01-16
SG11201400988SA (en) 2014-07-30
SG10201505664WA (en) 2015-09-29
MX2014004814A (es) 2014-05-27
EP2768506A2 (en) 2014-08-27
TW201333003A (zh) 2013-08-16
KR20140094559A (ko) 2014-07-30
EA201490610A1 (ru) 2014-09-30
DOP2014000081A (es) 2014-07-15
TW201542567A (zh) 2015-11-16
WO2013059559A2 (en) 2013-04-25
IL231894A0 (en) 2014-05-28
CO6910198A2 (es) 2014-03-31
EP2768506A4 (en) 2015-08-19
AR088793A1 (es) 2014-07-10
ZA201402392B (en) 2017-09-27
CN103957910A (zh) 2014-07-30
AU2012325971A1 (en) 2014-04-17
PE20141359A1 (es) 2014-10-13
UY34406A (es) 2013-05-31
CA2851801A1 (en) 2013-04-25

Similar Documents

Publication Publication Date Title
BR112014008727A2 (pt) composto, composição farmacêutica, uso do composto ou sal, métodos para o tratamento de e/ou a prevenção de uma doença ou condição, para a intensificação da resposta imune em um indivíduo, e para regular por regulação positiva uma resposta imune a jak/stat em um indivíduo
BR122014013631B8 (pt) compostos antivirais, seu uso e composição farmacêutica compreendendo os mesmos
BR112014011162A2 (pt) derivados purínicos para o tratamento de infecções virais
CY1122291T1 (el) Αναστολeις ιικου αναδιπλασιασμου
BR112015013695A2 (pt) composição farmacêutica, e, métodos para tratamento e para prevenção de uma infecção por hiv
BR112015011036A2 (pt) derivados de 2-amino-quinazolina substituídos heterocíclicos para o tratamento de infecções virais
BR112015000615A2 (pt) purinas macrocíclicas para o tratamento de infecções virais
BRPI0714803B8 (pt) compostos peptidomiméticos de smac, seus usos, e composição farmacêutica
BR112013032974A2 (pt) "derivados de 1,6-diazabiciclo [3,2,1]-octan-7-ona, seus usos, e composições farmacêuticas".
BR112015007366A2 (pt) derivados de acilaminopirimidina para o tratamento de infecções virais e outras doenças
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
BR112014000371A2 (pt) derivados de trifluormetil-oxadiazol e uso dos mesmos no tratamento de doença
BR112014014740A8 (pt) composto, composição farmacêutica, método para melhorar ou tratar infecção viral, para inibir a replicação de vírus ou tratar infecção viral e usos quantidade efetiva de composto ou de sal farmaceuticamente aceitável deste ou de composição farmacêutica
BR112015020118A2 (pt) derivados de 2-aminopirimidina para o tratamento de infecções virais
CL2012003632A1 (es) Compuestos derivados de pirazolo[1,5-a]pirimidinas o una sal farmaceuticamente aceptable de los mismos; composicion farmaceutica que los comprende; y su uso para tratar una infeccion por virus pneumovirinae o una infeccion por virus sincicial respiratorio.
BR112015007586A2 (pt) derivados de pirrolo[3,2-d]pirimidina para o tratamento de infecções virais e outras doenças
BR112014015845A2 (pt) derivados de azetidina, composições farmacêuticas e seu uso
BR112015029512A8 (pt) derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas
BR112015007742A2 (pt) composto, composição farmacêutica, método para a profilaxia ou tratamento da infecção pelo hiv ou para a profilaxia, tratamento, ou retardo do início da aids em um indivíduo, e, uso de um composto
BR112013025987A2 (pt) derivados de pirimidina para o tratamento de infecções virais
BR112013027096A2 (pt) compostos de benzotiazol e seu uso farmacêutico
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
BR112018070536A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
BR112013021599A2 (pt) (piridin-4-il)benzilamidas como moduladores alostéricos do nachr alfa 7
BR112017028456A2 (pt) composto, e, método de prevenção e/ou tratamento de hiv

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2484 DE 14-08-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]